Induce Biologics

Executive Summary

Induce Biologics is a San Diego-based regenerative medicine company developing bioimplants for natural bone regeneration using its proprietary Natural Matrix Protein (NMP) technology. NMP processes human bone to unlock bioactive growth factors, mimicking the body's innate healing cascade. The company offers particulate, strip, and fiber products targeting orthopedic and spine markets, addressing a significant unmet need for osteoinductive grafts that avoid synthetic additives. Since its founding in 2015, Induce has focused on preclinical and early clinical validation, positioning itself as a potential alternative to autografts and recombinant BMPs. While still private with limited disclosed funding, its technology could appeal to surgeons seeking safer, more effective bone graft substitutes. Key challenges include scaling manufacturing, demonstrating clinical superiority, and navigating regulatory pathways. The company's early-stage profile suggests high risk but transformative potential in the multibillion-dollar orthopedic biologics market.

Upcoming Catalysts (preview)

• Q3 2026FDA 510(k) clearance for NMP particulate product60% success
• Q1 2027Completion of first-in-human clinical trial for spine fusion40% success
• H2 2026Strategic partnership with major orthopedic company30% success